Skip to main content
SpringerLink
Log in

Antidementiva

  • Chapter
Arzneiverordnungs-Report 2001

  • 62 Accesses

Zusammenfassung

Demenzen sind Krankheiten des höheren Lebensalters, aber keine unausweichliche Folge des Alterns. Ab dem 60. Lebensjahr steigt die Prävalenz sowohl der primär degenerativen wie auch der vaskulären Demenzerkrankungen rasch an. Sie beginnt mit 3% bei den 65–74jährigen und erreicht 47% bei den über 85jährigen (Evans et al. 1989). Am häufigsten sind die Alzheimersche Krankheit und vaskuläre Demenzen. Bei 10–15% der Demenzkranken liegen potentiell reversible Grundkrankheiten vor, bei denen eine partielle oder vollständige Rückbildung durch spezifische Therapie erzielbar ist.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Battaglia A., Bruni G., Ardia A., Sacchetti G. (1989): Nicergoline in mild to moderate dementia. A multicenter, double-blind, placebo-controlled study. J. Am. Geriatr. Soc. 37: 295–302.

    PubMed  CAS  Google Scholar 

  • Bauer J. (1994): Klinische Diagnostik und Therapiemöglichkeiten der Demenz vom Alzheimer-Typ. Fortschr. Neurol. Psychiat. 62: 417–432.

    Article  PubMed  CAS  Google Scholar 

  • Benkert O., Hippius H. (1996): Psychiatrische Pharmakotherapie, 6. Aufl. Springer, Berlin Heidelberg New York.

    Google Scholar 

  • Birks J., Iakovidou V., Tsolaki M. (2000): Rivastigmine for Alzheimer’s disease. Cochrane Database Syst. Rev. 2: CD001191.

    PubMed  Google Scholar 

  • Birks J.S., Melzer D. (2000): Donepezil for mild and moderate Alzheimer’s disease. Cochrane Database Syst. Rev. 2: CD001190.

    Google Scholar 

  • Bundesgesundheitsamt (1991): Empfehlungen zum Wirksamkeitsnachweis von No-otropika im Indikationsbereich „Demenz“ (Phase III). Bundesgesundheitsblatt 7/91: 342–350.

    Google Scholar 

  • Committee for Proprietary Medicinal Products (CPMP) (1998): Note for guidance on medicinal products in the treatment of Alzheimer’s disease.

    Google Scholar 

  • Corey-Bloom J., Anand R., Veach J. for the ENA 713 B352 Study Group (1998): A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tart-rate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int. J. Geriatr. Psychopharmacol. 1: 55–65.

    CAS  Google Scholar 

  • Croisile B., Trillet M., Fondarai J., Laurent B., Mauguière F., Billardon M. (1993): Long-term and high-dose piracetam treatment of Alzheimer’s disease. Neurology 43: 301–305.

    Article  PubMed  CAS  Google Scholar 

  • Doody R.S., Stevens J.C., Beck C., Dubinsky R.M., Kaye J.A., Gwyther L. et al. (2001): Practice parameter: Management of dementia (an evidencebased review). Report of the Quality Standards Subcommittee of the American Academy of Neurology 56:1154–1166.

    CAS  Google Scholar 

  • Drew S., Davies E. (2001): Effectiveness of Ginkgo biloba in treating tinnitus: double blind, placebo controlled trial. Brit. Med. J. 322:1–6.

    Article  Google Scholar 

  • Evans D.A., Funkenstein H.H., Albert M.S., Scherr P.A., Cook N.R., Chown M.J. et al. (1989): Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported. JAMA 262: 2551–2556.

    CAS  Google Scholar 

  • Food and Drug Administration (1989): Peripheral and Central Nervous System Drugs Advisory Committee Meeting, July 7,1989. Rockville MD: Dept. of Health and Human Services, Public Health service 1989: 227.

    Google Scholar 

  • Gaitz C.M., Varner R.V., Overall J. E. (1977): Pharmacotherapy for organic brain syndrome in late life. Evaluation of an ergot derivative vs placebo. Arch. Gen. Psychiatry 34:839–845.

    Article  PubMed  CAS  Google Scholar 

  • Gauthier S. (1999): Do we have a treatment for Alzheimer disease? Yes. Arch. Neurol. 56: 738–739.

    Article  CAS  Google Scholar 

  • Hollister L., Gruber N. (1996): Drug treatment of Alzheimer’s disease. Effects on caregiver burden and patient quality of life. Drugs Aging 8: 47–55.

    Article  PubMed  CAS  Google Scholar 

  • Kanowski S., Herrmann W.M., Stephan K., Wierich W., Hörr R. (1996): Proof of efficacy of the Ginkgo biloba special extract Egb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 29: 47–56.

    Article  PubMed  CAS  Google Scholar 

  • Kleijnen J., Knipschild P. (1992): Ginkgo biloba. Lancet 340: 1136–1139.

    Article  PubMed  CAS  Google Scholar 

  • Kugler J., Oswald W.D., Herzfeld U., Seus R., Pingel J., Welzel D. (1978): Langzeittherapie altersbedingter Insuffizienzerscheinungen des Gehirns. Dtsch. Med. Wochenschr. 103: 456–462.

    Article  PubMed  CAS  Google Scholar 

  • Le Bars P.L., Katz M.M., Berman N., Itil T.M., Freedman A.M., Schatzberg A.F. (1997): A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 278: 1327–1332.

    Article  PubMed  Google Scholar 

  • Leber P. (1990): Guidelines for the clinical evaluation of antidementia drugs. Food and Drug Administration. Rockville, MD, USA.

    Google Scholar 

  • Marin D.B., Davis K.L. (1995): Experimental therapeutics. In: Bloom F.E., Kupfer D.J. (eds.): Psychopharmacology: The fourth generation of progress. Raven Press Ltd., New York, pp. 1417–1426.

    Google Scholar 

  • Mulnard R.A., Cotman C.W., Kawas C., van Dyck C.H., Sano M., Doody R. et al. (2000): Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 283: 1007–1015.

    Article  PubMed  CAS  Google Scholar 

  • O’Brien J.T., Ballard C.G. (2001): Drugs for Alzheimer’s disease. Brit. Med. J. 323: 123–124.

    Article  Google Scholar 

  • Orgogozo J.M., Forette F. for the MMM 300 Group (2000): Efficacy of memantine in mild to moderate vascular dementia (the MMM 300 Trial). Sixth Int. Stockholm /Springfield Symposium on Advances in Alzheimer Therapy. April 5–8, 2000.

    Google Scholar 

  • Parfitt K. (1999): Martindale. The complete drug reference. 32nd ed., Pharmaceutical Press, London, p. 1386.

    Google Scholar 

  • Perry E.K. (1986): The cholinergic hypothesis - ten years on. Brit. Med. Bull. 42: 63–69.

    PubMed  CAS  Google Scholar 

  • Pryse-Phillips W. (1999): Do we have drugs for dementia? No. Arch. Neurol. 56: 735–737.

    Article  PubMed  CAS  Google Scholar 

  • Reisberg B., Schneider L., Doody R., Anand R., Feldman H. et al. (1997): Clinical global measures of dementia. Alz. Dis. Assoc. Dis. 11 (Suppl. 3): 8–18.

    Google Scholar 

  • Reisberg B., Windscheif U., Ferris S.H., Hingorani V.H., Stöffler A., Möbius H.-J. (2000): Memantine in moderately severe to severe Alzheimer’s disease (AD): results of a placebo-controlled 6-month trial. Neurobiology of Aging 21 (1S): S275.

    Article  Google Scholar 

  • Rogers S.L., Farlow M.R., Doody R.S., Mohs R., Friedhoff L.T. and the Donepezil Study Group (1998): A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 50:136–145.

    Article  PubMed  CAS  Google Scholar 

  • Saletu B., Paulus E., Linzmayer L., Anderer P., Semlitsch H.V., Grünberger J., Wicke L., Neuhold A., Podreka I. (1995): Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology 117: 385–395.

    Article  PubMed  CAS  Google Scholar 

  • Schellenberg R., Todorova A., Wedekind W, Schober F., Dimpfel W. (1997): Pathophysiology and psychopharmacology of dementia - a new study design. 2. Cyclandelate treatment - a placebo-controlled double-blind clinical trial. Neuro-psychobiology 35: 132–142.

    CAS  Google Scholar 

  • Small G.W. (1998): Treatment of Alzheimer’s disease: current approaches and promising developments. Am. J. Med. 104 (4A): 32S–38S.

    Article  PubMed  CAS  Google Scholar 

  • Standaert D.G., Young A.B. (1996): Treatment of central nervous system degenerative disorders. In: Hardman J.G. et al. (eds.): Goodman & Gilman’s The pharmacological basis of therapeutics,9th ed., New York, pp. 503–519.

    Google Scholar 

  • Thompson T.L. II, Filley C.M., Mitchell W.D., Culig K.M., LoVerde M., Byyny R.L. (1990): Lack of efficacy of hydergine in patients with Alzheimer’s disease. N. Engl. J. Med. 323: 445–448.

    Article  PubMed  Google Scholar 

  • Van Dongen M.C.J.M., van Rossum E., Kessels A.G.H., Sielhorst H.J.G., Knipschild P.G. (2000): The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J. Am. Ger.Soc. 48: 1183–1194.

    Google Scholar 

  • Vernon M.W., Sorkin E.M. (1991): Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs Aging 1:17–35.

    Article  PubMed  CAS  Google Scholar 

  • Winblad B., Poritis N. (1999): Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriat. Psychiatry 14:135–146.

    Article  CAS  Google Scholar 

Download references

Authors
  1. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Germany

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln, Germany

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schwabe, U. (2001). Antidementiva. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2001. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56434-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56434-5_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-42079-8

  • Online ISBN: 978-3-642-56434-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation